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Abstract: This study was designed to investigate the expression of the T-box transcription 
factor 4 (TBX4), a tumor biomarker that was previously identified by proteomics, in 
pancreatic ductal adenocarcinoma (PDAC) and evaluate its clinical utility as a potential 
prognostic biomarkers for PDAC. The expression of TBX4 was detected in 77 stage II 
PDAC tumors by immunohistochemistry, and the results were analyzed with regard to 
clinicopathological characteristics and overall survival. Moreover, Tbx4 promoter 
methylation status in primary PDAC tumors and normal adjacent pancreas tissues was 
measured by bisulfite sequencing. Among 77 stage II PDAC tumors, 48 cases (62.3%) 
expressed TBX4 at a high level. No significant correlation between TBX4 expression and 
other clinicopathological parameters, except tumor grade and liver metastasis recurrence, 
was found. The survival of patients with TBX4-high expression was significantly longer 
than those with TBX4-low expression (P = 0.010). In multivariate analysis, low TBX4 
expression was an independent prognostic factor for overall survival in patients with stage 
II PDAC. TBX4 promoter methylation status was frequently observed in both PDAC and 
normal adjacent pancreas. We conclude that a low level of TBX4 expression suggests a 
worse prognosis for patients with stage II PDAC. Down-regulation of the TBX4 gene in 
pancreas is less likely to be regulated by DNA methylation.  
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1. Introduction  
Pancreatic ductal adenocarcinoma (PDAC) represents one of the most aggressive malignancies with 
a high mortality rate. It is the fourth leading cause of cancer death in the United States, and the sixth 
leading cause of death from malignant disease in China [1,2]. PDAC is not sensitive to radiation 
therapy and chemotherapy, and surgical resection remains its only curative option. However, because 
of the lack of typical symptoms and/or physical signs indicating early diagnosis, only 20% of patients 
diagnosed with PDAC are candidates for surgical resection. Despite curative resection, the long-term 
survival rate of these PDAC patients is still low (less than 20%), with a median overall survival of 18 
to 24 months [3,4]. Some clinicopathological parameters such as tumor size, stage, and lymph node 
metastasis have been proven to be reproducible prognostic determinants in pancreatic cancer. 
However, all these factors are far less than sufficient to explain the individual variability, therefore, 
there is still a need for reliable prognostic markers for the patients with PDAC who undergo resection.  
T-box transcription factor 4 (TBX4) was first described as a transcription factor involved in the 
regulation of hindlimb outgrowth and specification during embryonic development [5,6]. In a previous 
study, we identified TBX4 up-regulated in PDAC tissues by a proteomic approach [7]. It was the first 
time that TBX4 was associated with cancer. Kelemen et al. [8] recently reported that a TBX4 
polymorphism may contribute to breast cancer risk. TBX4 is located on chromosome 17q23, which 
has been shown to be amplified in breast cancer and pancreatic cancer. TBX4 is very similar to TBX5 
in its genomic organization and function during limb development. Most recently, Yu et al. [9] found 
that TBX5 may exert its role as a functional tumor suppressor by inducing tumor cell apoptosis and 
suppressing tumor cell proliferation and metastasis. Furthermore, loss of TBX5 expression in colon 
cancer is epigenetically controlled by promoter methylation and associated with poor prognosis [9]. 
Based on the above evidence, we speculate that TBX4 might also play a putative role in the 
development of pancreatic cancer. However, the clinicopathological and prognostic significance of 
TBX4 for PDAC patients have not been well characterized; most resectable pancreatic cancer are in 
stage II, and there is very little information on the prognosis of this subgroup of PDAC patients. 
Therefore, in this study, we examined TBX4 expression in 77 stage II PDAC tumors to determine 
whether TBX4 expression was associated with survival and other clinicopathological features in this 
resectable subgroup. Moreover, the promoter methylation status in PDAC tumors and normal adjacent 
pancreas tissues was also examined to determine whether TBX4 expression in pancreatic cancer was 
epigenetically controlled.  
2. Results and Discussion 
2.1. Expression of TBX4 in PDAC Tissues and Normal Adjacent Pancreas 
Immunohistochemical stain for TBX4 showed cytoplasm and nuclear staining patterns in both 
malignant and normal pancreatic ductal epithelial cells, but not in acinar cells, islet cells or stromal Int. J. Mol. Sci. 2011, 12 
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fibroblasts. Fifteen PDAC tumors showed no TBX4 staining while the other 62 PDAC cases showed 
TBX4 expression with different staining density. The mean percentage of TBX4 labeling cancer cells 
to total cancer cells (labeling ratio) in 77 PDAC samples was 38.8% ± 16.4%. None of the normal 
pancreatic ducts showed a TBX4 labeling ratio of more than 25%. In this study, 48 PDAC cases with a 
labeling ratio ≥25% were classified as high level of TBX4 expression, wherease those showing a 
labeling ratio <25% were classified as low level of TBX4 expression. Representative micrographs of 
PDAC tumors with high and low level of TBX4 expression are shown in Figure 1.  
Figure 1. Representative micrographs showing pancreatic ductal adenocarcinoma (PDAC) 
with high TBX4 expression with cytoplasmic and nuclear staining (A) and low TBX4 
expression (B). Original magnification, ×400. 
 
2.2. Correlation of Clinicopathological Features with TBX4 Expression 
Table 1 shows the relationship between TBX4 expression level and other clinicopathological 
factors of the study population. TBX4 expression levels showed an inverse correlation with higher 
grading (P = 0.015). Better differentiated PDAC tumors (Grade 1 and 2) more frequently expressed 
high level of TBX4 expression (45/48, 93.8%) than their poorly differentiated (Grade 3) counterparts 
(3/48, 6.2%). Liver metastasis recurrence was more frequently seen in the TBX4-low expressing group 
than the TBX4-high group (51.7% vs. 20.8%, P = 0.005). No significant association was identified 
between TBX4 expression and patient’s age, gender, tumor size, margin status, lymphnode metastasis 
and angiolymphatic invasion. 
Table 1. Clinicopathological features and correlation of TBX4 expression in stage II PDACs. 
Characteristics 
No. of cases 
(n = 77) 
TBX4—high 
(n = 48) 
TBX4—low 
(n = 29) 
P value 
Age (years)        
<60 27  16  11  0.682 
≥60  50 32  18  
Gender        
Female   32  20  12  0.980 
Male  45 28  17  Int. J. Mol. Sci. 2011, 12 
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Table 1. Cont. 
Characteristics 
No. of cases 
(n = 77) 
TBX4—high 
(n = 48) 
TBX4—low 
(n = 29) 
P value 
Tumor size ( cm)        
≤2.0 17  12  5  0.426 
>2.0  60 36  24  
Grade        
1 20  14  6  0.015 
2  45 31  14  
3 12  3  9   
Margin status        
Negative 58  35  23  0.537 
Positive 19  13  6   
Lymph node status        
Negative 23  15  8  0.734 
Positive  54 33  21  
Liver metastasis recurrence        
Negative 52  38  14  0.005 
Positive  25 10  15  
Lymphatic invasion        
Negative 20  12  8  0.803 
Positive  57 36  21  
Venous invasion        
Negative 31  21  10  0.422 
Positive  46 27  19  
2.3. Correlation of TBX4 Expression Level and Overall Survival 
To further investigate the prognostic significance of TBX4, we first performed univariate analysis 
to identify factors which might affect the survival of PDAC patients. After surgical resection, the 
median follow-up time was 25 months. As seen in Table 2, overall survival significantly correlated 
with margin status, lymph node status, liver metastasis recurrence, venous invasion and TBX4 
expression levels, but not with age, gender, tumor size, histopathological grading, lymphatic invasion 
(Table 2). Kaplan-Meier analysis revealed that low TBX4 level in PDAC tissues significantly correlated 
with markedly reduced overall survival (P = 0.010) (Figure 2). Additionally, we performed multivariate 
analysis to exclude the confounder effect. Cox proportional hazard model analysis confirmed that low 
TBX4 expression was an independent predictor for reduced overall survival of PDAC patients (Table 2).  
Table 2. Univariate analysis of overall survival in patients with stage II PDACs. 
Variables 
Univariate Multivariate 
HR (95% CI)  P  HR (95% CI)  P 
Age (years) 
<60 vs. ≥60 
1.049 (0.641–1.716)  0.846  -  - 
Gender 
Female vs. male 
1.534 (0.939–2.506)  0.079  -  - Int. J. Mol. Sci. 2011, 12 
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Table 2. Cont. 
Variables 
Univariate Multivariate 
HR (95% CI)  P  HR (95% CI)  P 
Tumor size (cm) 
≤2.0 vs. >2.0 
1.437 (0.811–2.548)  0.203  -  - 
Grade  
1 vs. 2 vs. 3 
1.017 (0.687–1.505)  0.714  -  - 
Margin status 
Negative vs. Positive 
1.886 (1.079–3.298)  0.021  1.886 (1.049–3.390)  0.034 
Lymph node status 
Negative vs. Positive 
1.721 (1.037–2.857)  0.030  1.932 (1.124–3.319)  0.017 
Liver metastasis recurrence 
Negative vs. Positive 
1.994 (1.217–3.269)  0.004  1.455 (0.800–2.648)  0.219 
Lymphatic invasion 
Negative vs. Positive 
1.110 (0.656–1.879)  0.692  -  - 
Venous invasion 
Negative vs. Positive 
1.638 (1.015–2.644)  0.037  2.107 (1.224–3.324)  0.006 
TBX4 
Low vs. High 
0.545 (0.337–0.881)  0.010  0.503 (0.285–0.888)  0.018 
 
Figure 2. Kaplan–Meier survival curves show that TBX4-low expression PDAC patients 
had a shorter survival than those with TBX4-high expression. The difference is statistically 
significant based on the log-rank test (P = 0.010). 
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2.4. Methylation of Promoter Region CpG Island of TBX4 in PDAC and Normal Pancreas 
The promoter region CpG island of the TBX4 gene were analyzed in 7 PDAC tumors (including 
both high and low expression) and 7 normal adjacent pancreas by bisulfite sequencing. As seen in  
Figure 3, the CpG island regions of TBX4 promoter were hypermethylated in both PDAC and normal 
pancreas tissues, thus indicating that expression of TBX4 in pancreas is less likely to be regulated by 
DNA methylation. 
Figure 3. Methylation status of 18 CpG sites in the TBX4 promoter region (−1842 to 
−1626) were analyzed in 7 PDAC tissues (T1-7) (3 cases were defined as low level of 
TBX4 expression, and the other 4 cases were defined as high level of TBX4 expression) 
and adjacent normal pancreas tissues (N1-7) (A); Black, gray, and white squares represent 
complete methylation, partial methylation, and unmethylation status at each CpG site, 
respectively (B). Methylation status was frequently observed in both PDAC and adjacent 
normal pancreas tissues.  
 Int. J. Mol. Sci. 2011, 12 
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2.5. Discussion 
TBX4 belongs to the TBX gene family, which encode a group of transcription factors characterized 
by a highly conserved DNA-binding motif (T-box) and play a key role during organogenesis and 
pattern formation in both vertebrate and invertebrate embryos. Recent studies suggest that several  
T-box family members are implicated in the progression of multiple cancers. For example, TBX2 and 
TBX3 are overexpressed in several cancers including pancreatic cancer, and can contribute to cancer 
development and progression due to their ability to suppress cellular senescence and E-cadherin 
expression [10,11]. However, different from TBX2 and TBX3, in a recent study, Yu et al. [9] recently 
found that loss of TBX5 gene expression in colon cancer tissues and cell lines was associated with 
promoter methylation. Furthermore, TBX5 methylation was detected in 68% (71/105) of primary 
colon tumors, and served as a potential biomarker for the prognosis of colon cancer. In a previous 
proteomic study, it was shown that TBX4 was overexpressed in a proportion of patients, however, the 
study included only a small sample size [7]. Our data also confirm previous associations between 
higher TBX4 expression and better differentiated type of PDAC, and extend previous findings 
indicating that a low level of TBX4 expression in stage II PDACs was associated with poor overall 
survival and was an independent prognostic factor for patients with stage II PDACs. These findings 
suggested that TBX4 may play a role in the progression of pancreatic cancer.  
In this study, although a nuclear pattern could be observed, the immunostaining of TBX4 protein 
was also located in the cytoplasm of cancer cells, which seems inconsistent with its function as a 
transcription factor. The cytoplasmic expression of TBX factors in cancer has been also identified in 
several other studies. For example, cytoplasmic overexpression of TBX2 had been identified in breast 
cancer tissues [12]. Qi et al. [7] also identified cytoplasmic TBX4 staining in pancreatic cancer tissues 
using another TBX4 antibody. Recently, Krcmery et al. characterized a functional nuclear export 
signal (NES) with an N-terminal DNA binding domain of all T-box proteins, by which TBX factors 
could shuttle between nuclear and cytoplasmic cell compartments, suggesting both nuclear and 
cytoplasmic roles for TBX family members [13,14]. Therefore, the above findings suggest that the 
cytoplasmic expression of TBX4 in pancreatic cancer could be associated with NES-directed protein 
shuttling; however, its functional roles in carcinogenesis remain unclear.  
Among the T-box family members, TBX4 and TBX5 are highly related in their genomic 
organization and gene function [15,16]. Considering the possible role of TBX5 as a tumor suppressor 
gene in colon cancer, we speculated that loss of the Tbx4 gene might be also epigenetically controlled. 
However, in this study, in the CpG islands known to regulate TBX4 expression, we found that these 
regions were hypermethylated in both PDAC and matched normal pancreas controls through bisulfate 
sequencing, thus indicating that different from TBX5 expression in colon cancer, DNA methylation is 
less likely to regulate TBX4 expression in pancreas. The discrepancy may lie in the different patterns 
of gene regulation of TBX factors in different organs. Similarly, Peres et al. also suggested that TBX2 
and TBX3, although highly homologous, have distinct roles in the transformation process of cancers 
where they are both overexpressed [17]. 
Currently available evidence indicates that TBX5 might exert its inhibitory action on cancer cells 
by inducing cancer cell apoptosis by targeting the extrinsic pathway, apoptotic Bax and Granzyme A 
signaling cascades, up-regulating the expression of a critical cell cycle inhibitor CDKN2A and an  Int. J. Mol. Sci. 2011, 12 
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anti-metastatic gene MTSS1, or inhibiting the expression of oncogene SBCG and pro-metastatic gene 
MTA2 [9]. However, until now the function of TBX4 is still not well understood. Although Tbx4 
might share similar molecular mechanisms with TBX5, further works need to be done to clarify its 
definite function in cancer development.  
Pancreatic cancer represents a devastating malignancy characterized by an extremely poor 
prognosis, rapid progression and resistance to chemo-radiotherapy. The majority of PDAC patients 
with surgically resectable cancer are at stage II disease, and identifying novel tumor biomarkers may 
lead to better prognosis prediction and more effective treatment options for this group of patients. In 
this study, we have reported for the first time a significant difference in the clinical outcome among 
stage II patents with different TBX4 expression levels. Our data suggests that TBX4 expression level 
might be a useful clinical predictive factor in PDAC patients undergoing surgically resection.  
This present cohort study is limited by its moderate sample size and retrospective design; therefore, 
further larger, multi-center and prospective clinical trials are needed to validate the clinicopathological 
and prognostic values of TBX4 in PDAC in the future. Moreover, the exact mechanism of TBX4 in 
pancreatic carcinogenesis also deserves further investigation. 
3. Experimental Section 
3.1. Patients 
A total of consecutive 95 patients with stage II PDAC who underwent standard curative resection at 
Department of General Surgery, Zibo Central Hospital (Zibo, China), Qianfo mountain Hospital (Jinan, 
China), Shandong Provincial hospital (Jinan, China), Qilu Hospital (Jinan, China) from 1998 to 2007 
were reviewed retrospectively. The median patient age at time of surgery was 64 years (range from  
38–84 years). All the patients routinely received postoperative 5-fluorouracil-based chemotherapy, and 
Gemcitabine-based chemotherapy and radiation therapy were given when recurrence or distant 
metastasis occurred. Follow-up was finished in April 2009. The median follow-up was 25 months 
(range, 8–102 months). The overall survival (OS) time was defined as the time from operation to 
cancer-caused death.  
Patients with PDAC were selected provided they received no preoperative chemotherapy and/or 
radiation, and follow-up data and archived formalin-fixed, paraffin-embedded specimens were 
available. Patients who died from postoperative complications were excluded. Above inclusion and 
exclusion criteria left 77 patients eligible for this study. The clinicopathological data of these patients 
are summarized in Table 1. The study was approved by the local research ethics committees at our 
institutions. All patients were informed with written consent obtained.  
3.2. Immunohistochemistry 
Immunohistochemical staining for TBX4 was performed on 4-μm formalin-fixed,   
paraflin-embedded archival tissue sections including 77 PDAC tumors and 12 normal adjacent 
pancreas tissues. Briefly, deparaffinized and rehydrated sections were boiled in sodium citrate buffer 
(pH 6.0) to perform antigen retrieval. Endogenous peroxidase activity was blocked by incubating the 
slides in methanol containing 3% hydrogen peroxide. Sections were incubated overnight at 4 °C with Int. J. Mol. Sci. 2011, 12 
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the polyclonal rabbit anti-human TBX4 antibody (Abcam, at a 1:200 dilution), and subsequently 
developed with an avidin-biotin-peroxidase complex method according to the manufacturer's 
recommendations (Envision system, Dako). Diaminobenzidine was used as a chromogen, and 
hematoxylin was used as a counterstain. Non-specific rabbit IgG was used as a negative control. The 
expression level of TBX4 was measured as a labeling ratio between the positively staining cancer cells 
to the total cancer cells as described previously [18]. PDAC cases were categorized into two groups: 
high TBX4 expression (labeling ratio ≥25%) and low level (labeling ratio <25%).  
3.3. Bisulfite Sequencing 
Methylation of promoter region CpG island of TBX4 gene（From −1842 bp to −1626 bp, Ref 
mRNA: NM_018488.2）was analyzed by bisulfite sequencing as described previously [19]. Briefly, 
genomic DNA was extracted from 7 PDAC and 7 adjacent normal pancreas frozen tissues using the 
QIAamp DNA Mini Kit (Qiagen, Germany) and was modified using the Zymo EZ DNA   
Methylation Kit (Zymo Research) according to the manufacturer’s instructions. Modified DNA was 
amplified using a 20 µL mixture including 1 × HotStarTaq buffer, 2.0 mM Mg
2+, 0.2 mM dNTP,  
0.2 µM of each primer (forward 5'-GAGAAAAGGAAGAGGTAAATTTTGA-3' and reverse   
5'-CATAAAATCCTCTACTA AACTCTTATCACA-3'), 1 U HotStarTaq polymerase (Qiagen, 
Germany) and 1 µL template DNA using an amplification program consisting of an initial incubation 
for 15 min at 95 °C, followed by 11 cycles of 94 °C for 20 s, 58 °C–0.5 °C per cycle for 40 s, 72 °C for 
1 min; 27 cycles of 94 °C for 20 s, 52 °C for 30 s, 72 °C for 1 min and a final 2 min incubation at 
72 °C. The products of PCR were purified using SAP and Exo I, and were then sequenced on ABI 
3130XL sequencing system (Applied Biosystems). 
3.4. Statistics 
The association of TBX4 protein expression with the clinicopathological characteristics was 
evaluated with Chi-square or Fisher’s exact test as appropriate. Overall survival in relation to TBX4 
expression patterns and other clinicopathological characteristics was evaluated by Kaplan–Meier 
survival curve and log-rank test. Statistically significant prognostic factors identified in univariate 
analyses were selected to enter multivariable analyses using a Cox proportional hazards model. 
Statistical analyses were performed using SPSS 16.0 software for Windows. The level of statistical 
significance was set at p < 0.05. 
4. Conclusions 
In this study, we examined whether TBX4 expression levels are associated with survival in a cohort 
of 77 Stage II PDAC patients. We found that a low level of expression of TBX4 significantly 
correlated with poor survival compared with high TBX4 phenotype. After adjusting for 
clinicopathological factors, TBX4 retains an independent prognostic factor for patients with stage II 
PDACs in the cohort. Additionally, different from TBX5 expression in colon cancer, the expression of 
TBX4 in PDAC seems not to be DNA methylation-regulated. Int. J. Mol. Sci. 2011, 12 
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